Yang M, Zhong P, Wei P
Int J Mol Sci. 2025; 26(5).
PMID: 40076679
PMC: 11900161.
DOI: 10.3390/ijms26052056.
Chacon J, Faizuddin F, McKee J, Sheikh A, Vasquez Jr V, Gadad S
Cancers (Basel). 2025; 17(5).
PMID: 40075661
PMC: 11899421.
DOI: 10.3390/cancers17050813.
Sun J, Song S, Liu J, Chen F, Li X, Wu G
NPJ Biofilms Microbiomes. 2025; 11(1):43.
PMID: 40069181
PMC: 11897378.
DOI: 10.1038/s41522-025-00678-x.
Li D, Lan X, Xu L, Zhou S, Luo H, Zhang X
Front Immunol. 2025; 16:1552010.
PMID: 40066456
PMC: 11891355.
DOI: 10.3389/fimmu.2025.1552010.
Yi D, Li T, Xiao Y, Zhang X, Hao Q, Zhang F
Bioeng Transl Med. 2025; 10(2):e10728.
PMID: 40060755
PMC: 11883108.
DOI: 10.1002/btm2.10728.
The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma.
Yao J, Ning B, Ding J
Gut Microbes. 2025; 17(1):2473504.
PMID: 40042184
PMC: 11901387.
DOI: 10.1080/19490976.2025.2473504.
Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade.
Li Z, Liu S, Liu D, Yang K, Xiong J, Fang Z
J Exp Clin Cancer Res. 2025; 44(1):84.
PMID: 40038799
PMC: 11881293.
DOI: 10.1186/s13046-025-03318-6.
Faecal microbiota transplantation combined with platinum-based doublet chemotherapy and tislelizumab as first-line treatment for driver-gene negative advanced non-small cell lung cancer (NSCLC): study protocol for a prospective, multicentre,....
Wei Y, Qin L, Wu X, Li D, Qian D, Jiang H
BMJ Open. 2025; 15(3):e094366.
PMID: 40037667
PMC: 11881178.
DOI: 10.1136/bmjopen-2024-094366.
Gut-X axis.
Lin X, Yu Z, Liu Y, Li C, Hu H, Hu J
Imeta. 2025; 4(1):e270.
PMID: 40027477
PMC: 11865426.
DOI: 10.1002/imt2.270.
Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It.
Zielinska M, Ciazynska M, Sulejczak D, Rutkowski P, Czarnecka A
Biomolecules. 2025; 15(2).
PMID: 40001572
PMC: 11853485.
DOI: 10.3390/biom15020269.
Association between antibiotics and treatment efficacy in metastatic urothelial carcinoma patients.
Braun A, Deng M, Hasler J, Bukavina L, Handorf E, Abbosh P
BMC Med. 2025; 23(1):117.
PMID: 40001066
PMC: 11863714.
DOI: 10.1186/s12916-024-03786-1.
Advancements in the Pathogenesis, Diagnosis, and Therapeutic Implications of Intestinal Bacteria.
Lu D, Ma X, Tao K, Lei H
Curr Issues Mol Biol. 2025; 47(2).
PMID: 39996827
PMC: 11853859.
DOI: 10.3390/cimb47020106.
Correlation between gut microbiota and tumor immune microenvironment: A bibliometric and visualized study.
Hu Z, Zhu H, Jin Y, Liu P, Yu X, Zhang Y
World J Clin Oncol. 2025; 16(2):101611.
PMID: 39995564
PMC: 11686564.
DOI: 10.5306/wjco.v16.i2.101611.
Targeting gut microbiota to regulate the adaptive immune response in atherosclerosis.
Giakomidi D, Ishola A, Nus M
Front Cardiovasc Med. 2025; 12:1502124.
PMID: 39957996
PMC: 11825770.
DOI: 10.3389/fcvm.2025.1502124.
Potential of lactylation as a therapeutic target in cancer treatment (Review).
Zhu Z, Zheng X, Zhao P, Chen C, Xu G, Ke X
Mol Med Rep. 2025; 31(4).
PMID: 39950331
PMC: 11836599.
DOI: 10.3892/mmr.2025.13456.
Gut microbiota and immune alteration in cancer development: implication for immunotherapy.
Lau H, Zhang X, Yu J
eGastroenterology. 2025; 1(1):e100007.
PMID: 39944250
PMC: 11770436.
DOI: 10.1136/egastro-2023-100007.
A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma.
Ballerini M, Galie S, Tyagi P, Catozzi C, Raji H, Nabinejad A
Nat Biomed Eng. 2025; .
PMID: 39939548
DOI: 10.1038/s41551-024-01318-z.
The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency.
Chandrasekaran P, Krausz M, Han Y, Mitsuiki N, Gabrysch A, Noltner C
Microbiome. 2025; 13(1):51.
PMID: 39934899
PMC: 11817180.
DOI: 10.1186/s40168-025-02028-7.
Tumor microbiome: roles in tumor initiation, progression, and therapy.
Zhang S, Huang J, Jiang Z, Tong H, Ma X, Liu Y
Mol Biomed. 2025; 6(1):9.
PMID: 39921821
PMC: 11807048.
DOI: 10.1186/s43556-025-00248-9.
The gut microbiome and cancer response to immune checkpoint inhibitors.
Gazzaniga F, Kasper D
J Clin Invest. 2025; 135(3).
PMID: 39895632
PMC: 11785914.
DOI: 10.1172/JCI184321.